PolyPeptide Group AG (XSWX:PPGN) FCF Margin % : 31.53% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PolyPeptide Group AG's Free Cash Flow for the six months ended in Dec. 2023 was CHF56.1 Mil. PolyPeptide Group AG's Revenue for the six months ended in Dec. 2023 was CHF177.8 Mil. Therefore, PolyPeptide Group AG's FCF Margin % for the quarter that ended in Dec. 2023 was 31.53%.

As of today, PolyPeptide Group AG's current FCF Yield % is -1.98%.

The historical rank and industry rank for PolyPeptide Group AG's FCF Margin % or its related term are showing as below:

XSWX:PPGN' s FCF Margin % Range Over the Past 10 Years
Min: -26.09 Med: -1.87 Max: 17.72
Current: -7.08

During the past 6 years, the highest FCF Margin % of PolyPeptide Group AG was 17.72%. The lowest was -26.09%. And the median was -1.87%.

XSWX:PPGN's FCF Margin % is ranked worse than
65.43% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.12 vs XSWX:PPGN: -7.08

PolyPeptide Group AG FCF Margin % Historical Data

The historical data trend for PolyPeptide Group AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG FCF Margin % Chart

PolyPeptide Group AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

17.72

2.82

-7.22

-26.09

-6.32

PolyPeptide Group AG Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial					-17.80	-36.58	-16.58	-60.45	31.53

Competitive Comparison of PolyPeptide Group AG's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPeptide Group AG's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's FCF Margin % falls into.

PolyPeptide Group AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PolyPeptide Group AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-19.095	/	302.135
	=	-6.32 %

PolyPeptide Group AG's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	56.056	/	177.806
	=	31.53 %

PolyPeptide Group AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPeptide Group AG (XSWX:PPGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PPGNz:UK

Address

Neuhofstrasse 24, Baar, Zug, CHE, 6340

Website

https://www.polypeptide.com

PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines